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                                           Abstract 
 
Background 
The therapeutic goal of HAART is sustained immune recovery and viral suppression. 
However some patients still have poor CD4 count responses despite achieving viral 
suppression. Such discordance immune response has been associated with poor 
clinical outcomes. We describe the prevalence of discordant immune response 
during the first 6-months of HAART and determine risk factors associated with this 
discordance at two large public sector clinics in South Africa. 
Methods 
We analysed data from 6 460 HIV-infected adults initiated onto first-line HAART at 
Goba and Phola Park clinics, in Johannesburg, South Africa between November 
2008 and December 2009. Multivariable logistic regression models were used to 
estimate adjusted odds ratios (AOR) for associations between discordant immune 
response and clinical and demographic factors. Models were adjusted for WHO 
clinical stage, baseline CD4 count, education level and HAART regimen. 
Results  
At initiation of HAART, most patients were female 592(64.6%) and 803(87.6%) were 
initiated on 3TC-d4T-EFV/NVP. The mean CD4 count was 155 cells/mm3 (±118.4 
sd), mean age was 38.5 years (±8.7 sd) and most patients had haemoglobin 
>11g/dL (n=645, 71.2%). By 6-months after initiation of HAART, 24% (n=220) of 
patients had a discordant immune response, 7% (n=67) discordant virologic 
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response and 21% (n=1359) had been lost to follow-up. In multivariable analysis, 
higher baseline CD4 cell count (CD4≥200cells/mm3): AOR=3.02; 95%CI 2.08-4.38; 
p<0.001) and moderate anemia (8-9.4 g/dL) at baseline (AOR=2.30; 95%CI 1.25-
4.59; p=0.007) were the strongest predictive factors for development of discordant 
immune response.  
Conclusions 
We found a significant proportion of patients with discordant immune response 6-
months after initiating HAART. Simple algorithms utilizing baseline characteristics 
can be developed for use in clinics in order to identify those patients at risk of 
development of discordant immune responses. Intensive monitoring of individuals at 
risk may improve clinical outcomes.    
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                                 CHAPTER ONE   
General Introduction  
This chapter gives an overview of the burden of discordant immunologic and 
virologic responses to antiretroviral therapy. The chapter also contains the 
background on discordant immunologic and virologic responses, a statement of the 
problem, justification of the study, objectives of the study and a review of relevant 
literature. 
1.1 Background information 
Significant progress has been made in the treatment of the acquired immune-
deficiency syndrome (AIDS) caused by the Human Immuno-deficiency Virus (1). The 
introduction of antiretroviral therapy has seen a significant fall in morbidity and 
mortality associated with HIV infection (2). Antiretroviral drug treatment has evolved 
from the initial monotherapy with Zidovudine in 1987 to the current triple therapy 
known as highly active antiretroviral therapy (HAART). This reduction in morbidity 
and mortality has been achieved due to the ability  of HAART to reduce HIV viremia 
to undetectable levels and in turn increase numbers of circulating peripheral CD4 
lymphocytes(3). However studies have shown that in clinical practice only 40-60% of 
the patients receiving HAART achieve this concordant response , 12-23%  have 
neither of the above responses and the remaining patients  exhibit what is termed a 
discordant response (3). There are two types of discordant responses: an adequate 
immunologic response in the absence of viral suppression and good viral 
suppression in the absence of immunologic recovery(4).The latter response, poor 
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immunologic response despite viral suppression(CD4-/VL+) has received greater  
attention because of  concerns over  poor prognosis associated with lack of immune 
reconstitution despite virological suppression(4).The long term reduction in the risk of 
developing opportunistic infection and tumors in patients receiving antiretroviral 
therapy is related to immunologic recovery(5). Studies on discordant immune 
responders have mainly been in developed countries where treatment is protease 
inhibitor (PI) based and involved treatment experienced patients (3). 
1.2 Statement of problem 
One of the biggest public health problems facing the world to date is the HIV/AIDS 
pandemic and its implications on global health, international development and 
security (6). Because of the high burden of HIV/AIDS, it is important that discordant 
responses to HAART are better understood because studies continue to show their 
association with increased risk of mortality and morbidity. Though there has been 
extensive research on discordant responses to HAART, most of these studies have 
been conducted in resource-rich settings and have also been focused on patient 
cohorts exhibiting all 4 types of discordance. Applicability/generalizability of these 
findings is a major issue as antiretroviral drug regimens in resource-rich settings are 
predominantly protease inhibitor based and the cohorts consists predominantly of 
treatment experienced patients.  Findings on this topic in limited-resource settings 
are still limited and also very few if any have vigorously examined the sub-group of 
patients failing to achieve CD4 responses despite virologic suppression. The 
financial burden associated with the development of AIDS defining illnesses and 
their clinical management which often requires frequent physician consultation and 
hospitalizations is also a cause for concern. 
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1.3 Justification for the study. 
Despite the relative frequency, information on the prevalence, risk factors and clinical 
significance of discordant immune response to HAART is still limited (4). The lack of 
knowledge on this sub-group of patients may contribute to inadequate clinical 
management as current HIV treatment guidelines do not provide guidance on this 
scenario.  Studies on the prevalence and predictors of this discordant response from 
resource-limited settings (LRS) where the treatment is primarily nucleoside reverse 
transcriptase inhibitor (NRTI) based are still limited. Also in this setting, patients often 
initiate treatment at advanced stages of immunosuppression and often have co-
morbidities that may compromise their response to treatment (7).  
1.4 Literature review 
1.4.1 Introduction  
HIV infection is typically associated with progressive CD4 cell depletion and 
consequent immunodeficiency (8-10). However, the introduction of HAART has seen 
a fall in morbidity and mortality associated with HIV infection (2). This is through the 
ability of HAART to suppress HIV viremia to undetectable levels and concomitantly 
resulting in an increased number of CD4 cells (11).However in clinical practice not all 
patients receiving HAART achieve this desired concordant response as 20-40% 
respond in a discordant manner (12). 
Some patients on HAART show a trend of sustained CD4 cell response despite 
constant viremia or do not show a significant increase in CD4 cell count despite viral 
suppression. These two scenarios are referred to as discordant response and are 
associated with an intermediate risk of developing an AIDS event or death (3, 12-
14). Immunologic only response without viral response has been attributed to lower 
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baseline CD4 count, presence of non synctium- inducing viruses, viruses with 
multiple resistance mutations and low level viral replication with viruses with reduced 
fitness(15, 16). Virologic only response without immune recovery may arise due to 
either failed immune reconstitution or excessive destruction of CD4 cells (17). The 
reconstitution of peripheral CD4 cells is a biphasic process with an initial rapid 
increase of memory CD4 cells succeeded by a slow increase of naïve CD4 cells (18, 
19). The second rise in CD4 cells may be due to expansion or sustenance of cell 
survival in the periphery and also by the central regeneration of cells by the thymus 
(17). Paradoxically, a few studies have shown contrasting results linking higher 
baseline CD4 cell count with development of discordant immune response (13, 20). 
This could be attributed to the different study settings as these studies were mainly 
conducted in resource- limited settings. 
 Previous studies conducted in resource rich settings show that discordant response 
occurs in 20-30% of patients six months to twenty-four months after initiating 
HAART(2). There is however paucity of data on discordant responders from 
developing countries. The Antiretroviral Therapy in Lower Income Countries 
Collaboration (ART-LINC) has written on the frequency of discordant responses in 
HIV treatment programs in Africa, Asia and South America. Information from 15 
countries showed the frequency of virologic only response to be 19.07% and 
immunologic only response to be 14.8% after 6 months of treatment (21). Another 
study by Tan et al. from the University of Alabama outpatient HIV clinic showed 
frequency of immunologic only response to be 15.8% and that of virologic only 
response to be 8.7%(22). Moore at el. from Vancouver, Canada had similar findings 
with frequency of virologic only responders being 15.7% and that of immunologic 
only responders being 11.7% (11). This variation in frequency of discordant 
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responses could be due to variation in sample sizes, definition of discordant 
response and study settings. Viral suppression has been defined differently within 
these studies with some studies using a cut-off value of 400copies/ml and others 
using 1000copies/ml.  
Despite the relative frequency of discordant immune response shown in resource 
rich settings, no study has been done in South Africa to ascertain its burden and 
associated hematologic and demographic factors. Our study will help quantify the 
burden of the condition and describe factors associated with the development of 
discordant response.   
1.4.2 Risk factors for developing discordant immune response 
The pathogenesis of discordant immune response is not well understood. It is 
thought to result from the interaction of viral, host and treatment related factors. 
The host factors associated with a discordant immune response include old age 
which has been associated with diminished immune response as a result of 
decreasing thymic activity with increasing age (2). A lower pre-treatment nadir CD4 
count which results from depletion of CD4 cells in the gut associated lymphoid tissue 
during initial primary HIV infection has also been associated with blunted immune 
recovery. This may lead to a slow or refractory reconstitution of immune function with 
antiretroviral therapy (23). Paradoxically, a few studies have shown contrasting 
results linking higher baseline CD4 cell count with development of discordant 
immune response (13, 20). This could be due to patients initiating treatment with a 
high baseline CD4 cell count resulting in minimal increase in CD4 cell count on 
follow up. 
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The patient gender and co- infection with opportunistic infections like Tuberculosis, 
Human T-Lymphotrophic Virus-1 (HTVL-1), HIV-2 and GB Virus C (GBV) has been 
also associated with discordant immune response (24-26).  
 Host genetics have been shown to play a part in the immune recovery. The 
multidrug resistance transporter gene MDR1 codes for P-glycoprotein which is 
essential for transportation of many different substrates including antiretroviral drugs. 
An over expression of P-glycoprotein lowers intracellular concentration of protease 
inhibitors and may affect reconstitution of CD4 cell production (2). Other studies 
have shown an association with genes responsible for T-lymphocyte turnover, 
activation and apoptosis (27). A combination of genes controlling T lymphocyte 
homeostasis and an allele that encodes IL-6 production have been shown to change 
CD4 cell recovery (26). 
 Treatment factors associated with discordant immune response include the 
combination of Tenofovir/Didanosine which is known to be Didanosine dose 
dependant (28). The hypothesized mechanism being the synergistic effect of both 
drugs’ metabolites in producing an imbalance in the purine pool of CD4 cells which 
induces cytolysis (29). The use of myelotoxic drugs such as Zidovudine and 
Cotrimoxazole has also been linked to poor immune response (2). Also poor 
adherence to antiretroviral therapy has been associated with a discordant immune 
response (30). 
1.4.3 Prognosis of discordant responders 
Studies in resource rich settings have shown a stronger correlation of long-term 
prognosis with viro- immunological responses after 6 months on HAART than with 
baseline values(2). Discordant response at 3-9 months after HAART initiation play a 
18 
 
crucial role in predicting long-term clinical outcomes in treatment naïve 
patients(31).The majority of studies have shown that discordant immune responders 
are associated with an intermediate risk of death and clinical progression when 
compared to complete responders(2). The UK CHIC study showed incidence rate 
ratio (IRR) of death of 3.35 with 95% CI (1.73-6.47) in both types of discordant 
responders. Studies by Moore et al (11) and Tan et al.(22) showed an average 
relative hazard (RH) of death 3.33 95% CI (1.64-7.08) among virologic only 
responders and 2.64 CI (1.89-3.96) among immunologic responders.   
Furthermore few studies have been done to assess the prognostic impact of 
discordant immune responders in HAART naïve patients and patients receiving non-
nucleoside reverse transcriptase inhibitors (NNRTI) based regimen which are 
common in resource limited settings. 
1.5 Study objectives  
1.5.1 General study objective 
The main objective of this study was to describe the prevalence discordant immune 
responders during the first 6-months of antiretroviral therapy and also to examine 
risk factors associated with this clinical scenario at two large public sector clinics in 
South Africa 
1.5.2 Specific objectives 
 To describe the prevalence of discordant immunologic and virological 
responders among patients receiving HAART at public sector clinics in 
South Africa. 
 To identify the factors associated with discordant immune response to 
antiretroviral therapy. 
19 
 
CHAPTER TWO:  METHODOLOGY 
Introduction  
Chapter two describes the study design and methodology. In this chapter the study 
population is described, selection of the study sample is illustrated and data sources 
and management are discussed. Details of study variables and definition of 
outcomes of interest is defined in this chapter. The chapter concludes with a 
synopsis of the data analysis plan and ethical considerations of the study.   
2.1 Study design 
We analysed prospectively collected cohort data for HIV-infected patients initiating 
HAART at two Ekurhuleni district Comprehensive Care Management and Treatment 
(CCMT) centres (Phola Park and Goba Clinics) in Johannesburg, South Africa.  
2.2 Study setting 
Ekurhuleni is the largest of the six districts of Gauteng province in South Africa. It 
has a population of 2 480 260 people and an HIV prevalence of 31.5% (32). Phola 
Park and Goba clinics were initially down referral clinics which started to initiate 
antiretroviral treatment in January 2009.  Down referral clinics are primary care 
clinics designated to maintain care of patients on antiretroviral therapy who are 
deemed stable by central HAART initiation centres. Since inception of the clinics, 
over 6000 HIV infected people have been enrolled into care with more than 3000 
currently receiving free antiretroviral treatment in accordance to the current South 
African National Department of Health Guidelines of 2010.  However during the 
study period, the 2004 HIV treatment guidelines were in use (see Table 2). Tables 1 
shows the patient follow-up schedule at these 2 clinics in accordance with these 
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guidelines. The 2004 guidelines which were employed during the study period had a 
two tier treatment readiness assessment process (33).  
Table 1: The two-tier treatment readiness assessment process  
Initial screening visit(2-4 weeks 
before starting treatment) 
Second visit(often 
accompanied the HAART 
commencement visit) 
HAART commencement visit. 
 
 Confirm the selection criteria: 
clinical and laboratory (make 
sure TB and pregnancy have 
been excluded). 
  Treat any opportunistic 
infection. 
  Patient’s information records 
need to be completed. 
  Patient must meet with the 
multi-disciplinary team for 
group and individual           
information sessions. 
  Treatment counsellor/patient 
advocate will discuss 
treatment with the patient. 
 28-day supply of 
Cotrimoxazole is given to 
patient. 
 Patient is given a date of 
return. 
 
 Clinical 
assessment 
 Information and 
education session 
 Pill count 
(Cotrimoxazole) 
 Adherence 
counselling for 
patient and 
treatment 
counsellor if 
available. 
 
 
 Re-assess patient’s 
readiness. 
 Do Cotrimoxazole pill 
count. 
 Provide detailed 
description of the drugs. 
 Discuss further 
information and 
adherence issues with 
the patient and his/her 
counsellor or advocate. 
 Re-enforce drug-dosing 
details before the 
patient leaves the clinic. 
 Ensure that instructions 
are clearly written on 
the container with a 
permanent marker. 
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Table 2: HAART monitoring schedule  
Regimen Drugs Monitoring test Frequency 
1a D4T/3TC/EFV  CD4 
 
 VL 
 ALT 
 Staging,6 monthly 
 6 monthly 
 symptomatic 
 
1b D4T/3TC/NVP  CD4 
 
 VL 
 
 
 ALT 
 Staging,6 monthly 
 6 monthly 
 
 Baseline, week 
2,4 and 
8.thereafter 6 
monthly 
National antiretroviral therapy guidelines. South Africa, 2004. 
Key: Staging: initial testing for all patients when referred for ART 
         Baseline: testing for ART eligible at initiation of ART  
         1a:Stavudine/Lamuvudine/Efavirenz 
         1b: Stavudine/Lamuvudine/Nevirapine 
Above is a table showing first line ART regimens in use during the study period and 
the recommended monitoring schedule. 
These clinics were selected because clinical data of the patients is captured 
electronically and such available for secondary analysis.  
2.3 Study population 
 The study population consisted of 6 460 HIV infected people enrolled at Phola Park 
and Goba clinics  CCMT centres in Ekurhuleni district from  inception to 31 
December 2009. 
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2.4 Study sample  
The study sample consisted of 917 adults patients initiated on to HAART at Phola 
Park and Goba clinics since between 01 November 2008 and 31 December 2009. 
This also included individuals who had been down referred from larger HIV-treatment 
units.  
Inclusion criteria  
Patients had to fulfil the following criteria in order to be included in the study: 
 patients older than 16 years at initiation of HAART.   
 patients who received standard first-line HAART for at least 3 months. 
 patients who had baseline CD4 count and the next scheduled CD4 
count within a 6 month period in their records.  
 patients who had viral load taken on the same day as the next 
scheduled CD4 count.  
 patients who were ART naïve at treatment initiation. 
Exclusion criteria 
 HIV infected patients not on treatment  
 patients with both incomplete CD4 count and viral load results. 
2.5 Data sources 
Patient clinical and demographic data at the treatment sites is captured and stored 
on an electronic patient management and decision support making system called 
TherapyEdgeT.M.. This system incorporates a data warehouse for aggregation of data 
from on-site installations of TherapyEdgeT.M- HIV. The system has a data capture 
module and rapid capture forms. Phola Park and Goba clinics record both 
demographic and clinical patient information using TherapyEdgeT.M . Trained data 
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capturers capture data from the patient files after each clinic visit. At the 
commencement visit the patient’s demographic and contact details are recorded on 
the HAART initiation form. At ensuing visits the patient’s vitals including weight as 
well as any symptoms and new diagnosis are recorded on the follow-up visit form. 
Blood tests results for CD4 cell count, HIV viral load, full blood count and liver 
function tests are tested and recorded onto the database as scheduled (Table 1). 
Data was extracted from Therapy-EdgeTM and exported to STATA version 11 
(STATA Corp., College Station, TX) for analysis.  
2.6 Study variables  
Main outcome  
The outcome of interest was the development of a discordant immune response. We 
defined viral suppression as a plasma HIV viral load less than 400 copies/mL at 6 
months after initiating antiretroviral therapy. Immune response was defined as an 
increase of 50 in the absolute CD4 count value at 6 months from the baseline value.  
Discordant immune response was defined  as viral suppression with immunological 
failure. Measurements within 3-9 months were used in this analysis as these patients 
are representative of the 6 month scheduled follow-up.  
N.B: Those with virologic failure accompanied with an immune response were not 
analyzed because their risk factors are different. 
Exposure variables. 
 Age (years) and Age groups categorized in years as:(16-24)( 25-44) (45-64) 
(>65) [34] 
 Gender (male/female) 
 Alcohol intake(yes/no) 
24 
 
 Smoking (yes/no) 
 Employment status as : (unemployed/ employed) 
 Level of education as: Illiterate/ Primary school / secondary  school / beyond 
secondary school                            
 BMI: Body Mass Index categorized as: (Underweight< 18.5)( Normal:18.5-
24.99)(Overweight25.0- 29.99)( Obese >=30) 
 Baseline CD4 count categorized as: (CD4<200cells/ µL)( CD4≥200cells/ µL)                                              
 Baseline Hemoglobin categorized as: (normal ≥ 11g/dl)( mild anaemia:9.5-
10.9g/dl)( moderate:8.0-9.4g/dl)(severe:≤7.9) 
 AST level categorized as:(Normal/Abovel normal) 
 ALT level categorized as:(Normal/Abovel normal) 
 HAART regimen 
 WHO clinical stage categorized as: stages 1, 2, 3 and 4. 
 History of previous Tuberculosis(yes/no) 
2.7 Data Quality Control. 
The data of patients receiving antiretroviral therapy at Goba and Phola park clinics is 
captured from their medical records onto TherapyEdge-HIV T.M , a medical 
management software . This electronic database is managed and maintained by a 
Data management and Quality assurance team from Right To Care (34).  
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In addition to these quality assurance measures observations which were deemed 
implausible were set to missing before analysis since verification was impossible. 
This included weight of above 200kgs.  
2.8 Data processing methods and Data Analysis. 
All data was analysed in STATA version 11 (STATA Corp., College Station, TX). The 
prevalence of discordant immune response was computed. The Chi-square test was 
used to compare differences in characteristics between categorical variables (e.g. 
demographic and hematological characteristics of those with discordant immune 
response compared to those with a concordant response). The Student ttest was 
used to compare means of the continuous variables such as age, CD4 cell count and 
viral load which were noted to be normally distributed.  
Preliminary analysis was conducted to compare patients who had missing data at six 
months and those who were included in the analysis. This comparison was done to 
determine whether significant differences existed between the two groups which may 
affect the generalizabity of findings and bias the results. 
 Factors that were significant at p≤0.2 in univariate analysis were considered for 
inclusion in multivariable logistic regression models to determine factors associated 
discordant immune response when controlling for other factors. Age was reported in 
10 year increments to provide sensible interpretation. WHO stage was retained in all 
models as it had been included priori. This is because of the intimate link between 
baseline CD4 cell count and WHO stage at ART initiation. 
We arrived at our final models using both forward selection and backward elimination 
techniques. The models were tested for goodness of fit using the Hosmer-Lemeshow 
goodness of fit test. Interaction between all the significant variables in the model was 
26 
 
also investigated. Collinearity was tested in all the regression models.  In our final 
model, we adjusted for WHO clinical stage, baseline CD4 count, education level and 
HAART regimen. The latter three variables had been significant in the univariate 
analysis.  Precision of estimate for odds ratios (OR) in the logistic regression model 
was at the 5 percent significance level (p=0.05). We also conducted a sensitivity 
analysis to demonstrate robustness of our study findings to variation in definition of 
CD4 response.  Categorized continuous variables such hemoglobin level was tested 
for trend in the final model.  
2.9 Ethical consideration.  
Patient confidentiality was maintained through allocation of unique identifiers to 
individual participants and removal of any personal identifiers before the data was 
given to the researcher. The researcher was unable to obtain informed consent 
because secondary data analysis was conducted and as such study participants 
could not be reached to consent to the study. Ethical approval was obtained from the 
University of The Witwatersrand Human Research Ethics Committee 
(Medical),ethics number M10944 (see appendix 1) and permission to conduct the 
study was obtained from the Ekhuruleni Ethical Panel (see appendix 2). 
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CHAPTER THREE:  RESULTS 
INTRODUCTION 
This chapter begins with a flow diagram illustrating how study sample was obtained. 
It then shows a comparison between those with complete data and those with 
missing data at 6 months (hence not eligible for analysis) in terms of exposure 
variables. Baseline characteristics of the study sample are then followed by a 
comparison of those who developed discordant immune response and those who 
had concordant response. The factors associated with development of discordant 
immune responses are then investigated using logistic regression analysis. The 
chapter concludes with sensitivity analysis. 
3.1 Cohort demographics 
The study population consisted of 6 460 adults enrolled on the antiretroviral program 
at Goba and Phola park clinics from the clinic inception to the 31st of December 
2009. Out of this total, 962 were excluded because besides appearing in the ART 
program register no additional information was recorded (e.g no HAART regimen 
and baseline haematological measurements), a further 4 581 were excluded 
because there had either missing initial or 6 month CD4 count/ Viral load or both. 
These included those with mistaken HAART regimens.  
Of the 917 eligible for analysis 810 made the study sample (590: concordant 
response (CD4+/VL+), 220: discordant immune response (CD4-/VL+). The remaining 
107 had responses either a discordant virologic response (CD4+/VL-) or were non-
responders (CD4-/VL-). These latter responses were not the subject of our study.  
Therefore the prevalence of discordant immune response which was the subject of 
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this analysis was 24%.All the above information is illustrated below in the flow 
diagram below. 
 
Fig 1: Flow chart of study participants 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Untreated with no 
additional data: n=962 
With additional data: n= 5 498 
Total participants: n= 6 460 
Missing either initial or 6 
month CD4/VL or both. Also 
with mistaken HAART 
regimen n= 4581 
Eligible for analysis: n=917 
n=590 (65%) 
VL
+
/CD4
+
: complete 
responders 
 
n=220(24%) 
VL
+
/CD4
-
: discordant 
immune responders 
 
67(7%): discordant 
virologic response. 
40(4%): non-responders 
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Table 3: Comparison of participants included in the analysis versus those with 
missing data at 6 months by baseline characteristics 
characteristics With missing data at 6 
months 
Eligible for analysis P-value 
 Age(years) (37.3)9.6 (38.5)8.9 0.009 
 Age groups(years) 
     16-24 
     25-44 
     45-64 
     ≥65 
 
109(7.69) 
961(71.03) 
281(20.77) 
7(0.52) 
 
31(3.39) 
689(74.54) 
196(21.42) 
6(0.66) 
 
 
 
 
0.001 
Gender: female 
              male 
883(64.97) 
476(35.03) 
592(64.56) 
325(35.44) 
 
0.839 
HAART  D4T-3TC-EFV 
            D4T-3TC-NVP 
            AZT-3TC-EFV 
            AZT-3TC-NVP 
            3TC-TDF-EFV 
            3TC-TDF-NVP 
 
644(51.44) 
 
137(10.54) 
 
476(38.02) 
 
803(87.57) 
 
81(8.83) 
 
33(3.60) 
 
 
 
 
 
0.001 
Baseline CD4 count(cells/ µL) (179.9)148.8 (155.7)118.4 0.003 
Baseline CD4 count 
  <200 cells/ µL 
  >200 cells/ µL 
 
901(66.35) 
457(33.65) 
 
660(72.85) 
256(27.95) 
 
 
0.004 
WHO clinical stage 
         1 
         2 
         3 
 
1 042(76.67) 
21(1.55) 
296(21.78) 
 
672(73.28) 
9(0.98) 
236(25.74) 
 
 
 
0.054 
Hemoglobin(g/dl) 
  Normal: ≥11 
 
897(70.02) 
 
645(71.19) 
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Mild anemia:9.5-10.9 
Mod anemia:8-9.4 
Severe anemia:≤7.9 
226(17.64) 
110(8.54) 
48(3.75) 
154(17.0) 
76(8.39) 
31(3.42) 
 
 
0.938 
History of TB 
      No 
      Yes  
 
1 286(94.63) 
73(5.37) 
 
814(88.77) 
103(11.23) 
 
 
0.001 
Smoking  
      No  
      Yes  
 
868(78.55) 
237(21.45) 
 
605(79.4) 
157(20.6) 
 
 
0.660 
Alcohol no 
              yes 
814(84.79) 
146(15.21) 
589(78.64) 
160(21.36) 
 
0.0001 
Body Mass Index 
Normal:18.5-24.99 
Underweight:<18.5 
Overweight:25-29.99  
Obese: ≥30 
 
509(49.8) 
116(11.38) 
239(23.39) 
158(15.46) 
 
372(49.01) 
64(8.43) 
198(26.09) 
125(16.46) 
 
 
 
 
0.151 
Occupation status 
Unemployed 
employed 
 
825(66.86) 
409(33.14) 
 
560(67.96) 
264(32.04) 
 
 
0.600 
Education level 
Illiterate 
10 school 
2nd school 
Tertiary school 
 
34(2.88) 
228(19.34) 
888(75.32) 
25(2.12) 
 
27(3.33) 
136(16.75) 
630(77.59) 
14(1.72) 
 
 
 
 
0.464 
Aspatate transaminase level      normal 
    Above normal 
800(69.14) 
357(30.86) 
591(66.03) 
304(33.97) 
 
0.135 
Alanine aminotransferase normal 
Above normal 
1 193(93.35) 
85(6.65) 
858(94.29) 
52(5.71) 
 
0.373 
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Key: n(%) for categorical variables and  (mean)standard deviation for continuous 
variable 
 
3.3 Comparison of  participants included in the analysis versus those with 
missing data at 6 months by baseline characteristics 
There is a significant difference in the mean ages of the two groups with those 
analyzed being a year older, though there was no significant difference in gender 
between the two groups. There was also a significant difference in the HAART 
regimen between the two groups with a higher proportion of those eligible for 
analysis (87.6%) initiating treatment on Stavudine based regimen compared to those 
with missing data at 6 months (51.4%) (p<0.001). A slightly higher proportion of 
those with missing data at 6 months (10.5%) were on a Zidovudine based regimen 
compared to (8.8%) who were analyzed. In addition an even higher proportion of 
those with missing data at 6 months (38%) were on Tenofovir based regimen 
compared to those analyzed (3.6%, p-value 0.001). 
A higher proportion of those analyzed (155 cells/ µL) started HAART with a 
significantly lower mean baseline CD4 count than those with missing data at 6 
months(179 cells/ µL) though there was marginally a significant difference (p-value 
0.003) in the WHO clinical stage at initiation of treatment in the two groups. 
There was also a significant difference in those with a history of Tb and alcohol use 
at commencement of HAART as a higher proportion of those analyzed (11%) were 
more likely (p-value 0.001) to have a history of Tb compared to those with missing 
data at 6 months (5.4%). Also a participant was more likely (p-value0.001) to use 
alcohol if there were analyzed (21.4%) compared to those who had missing data at 6 
months (15%)  
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However there was no significant difference in those analyzed and those with 
missing data at 6 months in the following variables, smoking, body mass index, 
hemoglobin level education level, occupational status, and hepatic enzymes (ALT, 
AST) (p>0.05). 
Table 4: Baseline characteristics of study sample 
characteristics Study sample 
Age(years) (38.4)8.7 
Age groups(years) 
     16-24 
     25-44 
     45-64 
     ≥65 
 
24(2.97) 
610(75.4) 
170(21.01) 
5(0.61) 
Gender: female 
              male 
530(84.13) 
100(15.87) 
HAART   D4T-3TC-EFV 
              D4T-3TC-NVP 
            AZT-3TC-EFV 
            AZT-3TC-NVP 
            3TC-TDF-EFV 
            3TC-TDF-NVP 
 
720(88.89) 
 
67(8.27) 
 
23(2.84) 
Baseline CD4 count(cells/ µL) (159)118 
Baseline CD4 count 
  <200 cells/ µL 
  >200 cells/ µL 
 
584(72.10) 
226(27.90) 
WHO clinical stage 
         1 
         2 
         3 
 
598(73.83) 
9(1.11) 
203(25.06) 
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Hemoglobin(g/dl) 
  Normal: ≥11 
Mild anemia:9.5-10.9 
Mod anemia:8-9.4 
Severe anemia:≤7.9 
 
577(72.13) 
135(16.88) 
61(7.63) 
27(3.38) 
History of TB 
      No 
      Yes 
 
721(89.01) 
89(10.89) 
Smoking  
      No  
      Yes 
 
540(79.30) 
141(20.70) 
Alcohol no 
              yes 
529(78.49) 
145(21.51) 
Body Mass Index 
Normal:18.5-24.99 
Underweight:<18.5 
Overweight:25-29.99  
Obese: ≥30 
 
327(48.16) 
55(8.10) 
181(26.66) 
116(17.08) 
Occupation status 
Unemployed 
employed 
 
492(67.86) 
233(32.14) 
Education level 
Illiterate 
10 school 
2nd school 
Tertiary school 
 
21(2.95) 
125(17.53) 
553(77.56) 
14(1.96) 
Aspatate transaminase level            
normal 
Above normal 
 
523(66.29) 
266(33.71) 
Alanine aminotransferase normal 761(94.77) 
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Above normal 42(5.23) 
Key: n(%) for categorical variables and  (mean)standard deviation for continuous 
variable. 
3.3: Baseline characteristics of study sample 
The mean age of the study sample was 38 (std 8.7) years and mean CD4 cell count 
was 159 (std 118). The majority of study participants were female 530(84%), were 
on Stavudine based regimen 720 (88%), had normal body mass index 327(48%), 
normal hemoglobin level 577(72%) and in WHO clinical stage 1 598(74%). It should 
be noted that no participant was classified as WHO clinical stage 4 at the time of 
initiation of treatment. 
Table 5:  
Comparison of discordant and concordant responders defined at 6-9 months 
characteristics (VL+/ CD4+) responders (VL+/ CD4-) responders p-value ψ 
Age(years) (38.0)8.6 (39.5)8.9 0.0276 
Age groups(years) 
     16-24 
     25-44 
     45-64 
     ≥65 
 
18(3.05) 
454(76.95) 
114(19.32) 
4(0.68) 
 
6(2.74) 
156(71.23) 
56(25.57) 
1(0.46) 
 
 
 
0.279 
Gender: female 
              male 
392(66.44) 
18(33.56) 
138(62.73) 
82(37.27) 
 
0.323 
HAART   D4T-3TC-EFV 
              D4T-3TC-NVP 
            AZT-3TC-EFV 
            AZT-3TC-NVP 
            3TC-TDF-EFV 
            3TC-TDF-NVP 
 
532(90.17) 
 
40(6.78) 
 
18(3.05) 
 
188(85.45) 
 
27(12.27) 
 
5(2.27) 
 
 
 
 
0.037 
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Baseline CD4 count(cells/ µL) (137.1)84.6 (218.7)167.9 0.0001 
Baseline CD4 count 
  <200 cells/ µL 
  >200 cells/ µL 
 
462(78.56) 
128(21.69) 
 
122(55.45) 
98(44.55) 
 
 
0.0001 
WHO clinical stage 
         1 
         2 
         3 
 
434(73.56) 
5(0.85) 
151(25.59) 
 
164(74.55) 
4(1.82) 
52(23.64) 
 
 
 
0.444 
Hemoglobin(g/dl) 
  Normal: ≥11 
Mild anemia:9.5-10.9 
Mod anemia:8-9.4 
Severe anemia:≤7.9 
 
415(71.31) 
104(17.87) 
38(6.53) 
25(4.30) 
 
162(74.31) 
31(14.22) 
23(10.55) 
2(0.92)*2  
 
 
 
 
0.017 
History of TB 
      No 
      Yes 
 
529(89.66) 
61(10.34) 
 
192(87.27) 
28(12.73) 
 
 
0.33 
Smoking  
      No  
      Yes 
 
393(79.23) 
103(20.77)*94 
 
147(79.46) 
38(20.54)*35 
 
 
0.948 
Alcohol no 
              yes 
390(78.95) 
104(21.05)*96 
139(77.22) 
41(22.78)*40 
 
0.630 
Body Mass Index 
Normal:18.5-24.99 
Underweight:<18.5 
Overweight:25-29.99  
Obese: ≥30 
 
234(46.15) 
40(7.89) 
147(28.99) 
86(16.96)*83 
 
93(54.07) 
15(8.72) 
34(19.77) 
30(17.44)*48 
 
 
 
 
0.117 
Occupation status 
Unemployed 
employed 
 
364(69.20) 
162(30.80)*64 
 
128(64.32) 
71(35.68)*21 
 
 
0.209 
Education level    
36 
 
Illiterate 
10 school 
2nd school 
Tertiary school 
12(2.30) 
92(17.66) 
404(77.54) 
13(2.50)*69 
9(4.59) 
33(17.19) 
149(77.60) 
1(0.52)*28 
 
 
 
0.138 
Aspatate transaminase level      normal 
    Above normal 
387(67.19) 
189(32.81)*14 
136(63.85) 
77(36.15)*7 
 
0.379 
Alanine aminotransferase normal 
Above normal 
552(94.52) 
32(5.48)*6 
209(95.43) 
10(4.57)*1 
 
0.605 
 
Key: n(%) for categorical variables and  (mean)standard deviation for continuous      
variable. 
             Missing values:* 
Ψ- p-values were obtained using chi 2 test and student ttest 
 
Discordant immune responders where more likely to be older when compared to 
concordant responders. In addition concordant responders were more likely to be on 
a Stavudine based HAART regimen when compared to discordant immune 
responders. However discordant immune responders were more likely to be on a 
Zidovudine and Tenofovir based regimens than concordant responders. 
Virologic only responders were more likely to initiate HAART with a higher baseline 
CD4 cell count than concordant responders. 
Moreover there was a significant difference in the hemoglobin level at initiation of 
HAART. Discordant immune responders were more likely to initiate HAART with 
moderate anemia and concordant responders were more likely to have initiated 
treatment with a normal hemoglobin level.   
However there was no difference among the groups with respect to the following 
variables:  
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Gender, history of Tuberculosis, smoking, WHO clinical stage, alcohol use, 
occupation status, level of education, body mass index and liver enzymes (AST, 
ALT). 
3.4: Risk factors associated with poor CD4 response 
Table 6:  
Univariate and Multivariate analysis of factors associated with discordant 
immune response. 
Variable  Univariate model 
Unadjusted Odds ratio   (CI)    P-value 
Multivariate model 
adjusted OR      (CI)   P-value 
Age(years) 1.02 (1.00-1.04)  0.028 1.02(1.00-1.04)0.031 
Gender: female 
              male 
1 
1.18 (0.85-1.66)  0.323 
 
HAART   D4T-3TC-EFV 
                D4T-3TC-NVP 
                AZT-3TC-EFV 
                AZT-3TC-NVP 
               3TC-TDF-EFV 
               3TC-TDF-NVP 
 
1 
 
1.91(1.14-3.20)   0.014 
 
0.78(0.29-2.15)  0.639 
 
Baseline CD4 count 
  <200 cells/ µL 
  >200 cells/ µL 
 
1 
2.90(2.08-4.03) 0.0001 
 
1 
3.02(2.08-4.38)0.001 
WHO clinical stage 
         1 
         2 
         3 
 
1 
2.12(0.56-7.98) 0.268 
0.91(0.63-1.31) 0.616 
 
Hemoglobin(g/dl) 
  Normal: ≥11 
Mild anemia:9.5-10.9 
 
1 
0.76(0.49-1.19) 0.230 
 
1 
0.88(0.54-1.45)0.629 
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Mod anemia:8-9.4 
Severe anemia:≤7.9 
1.55(0.90-2.68) 0.117 
0.20(0.05-0.88)0.032 
2.30(1.26-4.19)0.007 
0.36(0.08-1.63)0.188 
History of TB 
      No 
      Yes 
 
1 
1.26(0.78-2.04)0.335 
 
Smoking  
      No  
      Yes 
 
1 
0.99(0.65-1.50) 0.948 
 
Alcohol no 
              yes 
1 
1.11(0.73-1.67)0.630 
 
Body Mass Index 
Normal:18.5-24.99 
Underweight:<18.5 
Overweight:25-29.99  
Obese: ≥30 
 
1 
0.94(0.50-1.79)0.854 
0.58(0.37-0.91)0.017 
0.88(0.54-1.41)0.594 
 
Occupation status 
Unemployed 
employed 
 
1 
1.25(0.88-1.76)0.210 
 
Education level 
Illiterate 
10 school 
2nd school 
Tertiary school 
 
1 
0.48(0.18-1.24) 0.124 
0.49(0.20-1.19)0.116 
0.10(0.01-0.93) 0.043 
 
Aspatate transaminase level              normal 
    Above normal 
1 
1.16(0.83-1.61)0.379 
 
Alanine aminotransferase normal 
Above normal 
1 
0.83(0.40-1.71)0.605 
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3.4.1: Univariate analysis 
In the univariate analysis a ten year increase in age was significantly associated with 
2 percent greater chance of developing discordant immune response ( 
unAOR=1.02,p=0.028). Also, patients initiating treatment on Zidovudine based 
regimen had 1.9 greater odds of developing a discordant immune response 
compared to those initiating on Stavudine based regimen (p=0.014). Being on a 
Tenofovir based regimen was shown to be protective against developing a 
discordant immune response though this was not statistically significant (p=0.639). 
Initiating treatment with a baseline CD4 cell count greater than 200 was shown to be 
associated with a 2.9 greater odds of developing discordant immune response when 
compared to those with initial CD4 cell count less than 200(p<0.0001). 
In the univariate analysis initiating treatment with severe anemia was significantly 
associated with an 80% reduced odds of developing a discordant immune response 
(p=0.032) compared to those who had normal hemoglobin. A similar trend was noted 
in those who initiated treatment with mild anemia as it was associated with a 25 % 
reduced odds of developing discordant immune response though this was not 
statistically significant (p=0.230). A contrasting trend was noted in those who initiated 
treatment with moderate anemia as there were associated with just over 50% greater 
odds of discordant immune response compared to those who had a normal 
hemoglobin, though this was not significant (p=0.117).  
In addition, the univariate analysis showed a significant protective association of 
developing discordant immune response in patients who had an initial BMI class of 
overweight when compared to those who had normal BMI (OR=0.58, p=0.017), 
however the other BMI classes did not show a significant association. 
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Moreover, the univariate analysis showed a 90% reduced odds of developing 
discordant immune response in patients with tertiary level of education compared to 
those with were illiterate (p=0.043). However there was no significant association 
between developing immunologic discordant response and the other levels of 
education. No significant relationship was demonstrated with regards to the other 
variables in univariate analysis. 
3.4.2: Multivariate analysis 
In our final model, we adjusted for WHO clinical stage, baseline CD4 count, 
education level and HAART regimen. The latter three variables had been significant 
in the univariate analysis.  Precision of estimate for odds ratios (OR) in the logistic 
regression model was at the 5 percent significance level (p=0.05) 
Age was significantly associated with the development of discordant immune 
response. A ten year increase in age was associated with a 2 percent greater 
chance of developing discordant immune response (AOR=1.02,p=0.031).  
Also accounting for the other factors in the model, initiating treatment with a baseline 
CD4 count above 200 cells/ µL was significantly associated with a three times 
greater odds of developing discordant immune response when compared to the odds 
of those who initiated treatment with a CD4 count of less than 200 cells/ µL 
(p<0.0001). 
Initiating treatment with baseline moderate anemia was significantly associated with 
1.6 greater odds of developing discordant immune response accounting for the other 
variables in the model when compared to the odds those who initiated treatment with 
normal baseline hemoglobin. However there was no significant association with the 
other classes of anemia after controlling for confounding. 
41 
 
3.5: Interaction  
Interaction was investigated between all significant variables in the final model but 
none of the interaction terms were significant. 
3.6: Model assessment 
the  final model was assessed by the Hosmer Lemeshow goodness of fit test and 
were noted to be adequate. In addition a test for trend in baseline hemoglobin was 
investigated and no trend was established. 
 
3.7: Sensitivity analysis 
Table 7 
Univariate and Multivariate sensitivity analysis of factors associated with discordant immune responders 
Variable  Univariate model 
Odds ratio   (CI)       P-value 
Multivariate model 
AOR      (CI)   P-value 
Age(years) 1.02 (1.00-1.04)  0.059 1.02(1.00-1.04)0.030 
Age groups(years) 
     16-24 
     25-44 
     45-64 
     ≥65 
 
1 
1.18 (0.43-3.23)  0.740 
1.72 (0.61-4.86) 0.305 
0.95(0.09-10.50)  0.967 
 
Gender: female 
              male 
1 
1.09 (0.79-1.52) 0.594 
 
HAART D4T-3TC-EFV 
            D4T-3TC-NVP 
            AZT-3TC-EFV 
            AZT-3TC-NVP 
            3TC-TDF-EFV 
            3TC-TDF-NVP 
 
1 
 
2.00(1.19-3.37)  0.009 
 
1.11(0.43-2.87)  0.820 
 
 
 
 
Baseline CD4 count(cells/ µL) 1.01(1.01-1.02)0.0001  
Baseline CD4 count 
  <200 cells/ µL 
  ≥200 cells/ µL 
 
1 
5.51(3.91-7.77)0.0001 
 
1 
5.31(3.71-7.61)0.0001 
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WHO clinical stage 
         1 
         2 
         3 
 
1 
1.33(0.33-7.78)0.686 
0.89(0.61-1.30) 0.023 
 
Hemoglobin(g/dl) 
  Normal: ≥11 
Mild anemia:9.5-10.9 
Mod anemia:8-9.4 
Severe anemia:≤7.9 
 
1 
0.52(0.32-0.85) 0.009 
0.91(0.50-1.66) 0.011 
0.09(0.01-0.73)0.024 
 
 
History of TB 
      No 
      Yes 
 
1 
0.90(0.54-1.51)0.694 
 
Smoking  
      No  
      Yes 
 
1 
1.01(0.66-1.55) 0.962 
 
Alcohol no 
              yes 
1 
1.07(0.70-1.64)0.743 
 
Body Mass Index 
Normal:18.5-24.99 
Underweight:<18.5 
Overweight:25-29.99  
Obese: ≥30 
 
1 
0.70(0.35-1.39)0.311 
0.52(0.33-0.82)0.005 
0.80(0.49-1.31)0.372 
 
Occupation status 
Unemployed 
employed 
 
1 
1.04(0.73-1.49)0.832 
 
Education level 
Illiterate 
10 school 
2nd school 
Tertiary school 
 
1 
0.35(0.13-0.90) 0.029 
0.35(0.14-0.84)0.019 
0.18(0.03-1.03) 0.054 
 
Aspatate transaminase level      
normal 
    Above normal 
 
1 
0.86(0.61-1.22)0.409 
 
Alanine aminotransferase 
normal 
Above normal 
 
1 
0.79(0.37-1.68)0.544 
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We conducted sensitivity analysis by varying immune response and considering a 30 
percent increase from baseline CD4 as the desired response. The univariate 
analysis produced similar findings to those in the original analysis. However, only 
baseline hemoglobin level failed to be a significant risk factor for development of 
discordant response as in the original analysis. 
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Chapter four: Discussion 
4.1 Introduction  
The main objective of this study was to describe the burden of discordant immune 
response and identify the risk factors associated with discordant immune response 
to antiretroviral therapy at public sector clinics in South Africa. 
The results of our study showed the prevalence of discordant immune response to 
be 24% and concordant response to be 65%. These findings are similar to those 
obtained by several studies (2, 12, 14, 35, 36). Discordant immune response was 
shown to be associated with age, higher baseline CD4 cell count and moderate 
anemia.  
4.2 Representativeness of study sample 
4.2.1 Baseline characteristics of those with missing data at 6 months and those 
eligible for analysis. 
This study found that individuals who had missing data at 6 months were more likely 
to be younger on average of 37.3 years. This finding was similar to the one 
described by Dahab et al in South African cohort receiving HAART from public sector 
clinics were the average age was 37.5 years(std=37). However our study did not 
show that level of education as being associated with those lost to follow-up as 
Dahab et al showed. 
Also those with missing data at 6 months were more likely to have a higher baseline 
CD4 cell count than those eligible for analysis. In addition those with missing data at 
6 months were less likely to have had a history of Tuberculosis or use of alcohol than 
those eligible for analysis. These findings show that those with missing data at 6 
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months were more likely to have been of relatively better health than those eligible 
for analysis which is consistent with literature showing that individuals who view 
themselves as well are less likely to adhere to treatment than those who start 
treatment at more advanced state of poor health(37). This could have resulted in the 
study sample consisting mainly of older individuals of poorer health biasing our 
results. 
The above could have resulted in selection bias as those who were likely to develop 
the outcome of interest were eligible for analysis.  
4.2.2 Baseline characteristics of the study sample 
Discordant responders were more likely to be older than concordant responders and 
this could have biased the results though it was adjusted for in the multivariate 
model.  
There was a significant difference regarding HAART regimen among the groups of 
responders. Discordant immune responders were more likely to be on Zidovudine 
and Tenofovir based HAART regimens than concordant responders. In addition, 
discordant immune responders were more likely to have initiated treatment with 
moderate anemia than concordant responders.  
Discordant immune responders were more likely to have a higher baseline CD cell 
count when compared to concordant responders. 
All the above is congruent with literature were these factors have been associated 
with discordant response, except for moderate anemia. This will be explained further 
below. 
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4.3 Systematic overview of study findings 
4.3.1 HAART regimen as a risk factor for discordant immune response 
Our study showed that individuals on Zidovudine based HAART regimen were 
independently associated with1.9 greater odds of developing discordant immune 
response. This is in line with literature which shows that use of myelotoxic drugs like 
Zidovudine, Didanosine and Cotrimaxazole is associated with discordant immune 
response (2). However this was not significant after adjusting for other confounders. 
4.3.2 Age as a risk factor for discordant immune response 
After adjusting for potential confounders, a ten year increase in age was significantly 
associated with development of discordant immune response. This is similar to the 
findings of other studies were older age was associated with this outcome (5, 11, 14, 
36). This has been linked to the immune restoration which is largely dependent on a 
decreasing thymus activity with aging. 
4.3.3 Baseline CD4 cell count as a risk factor for discordant immune response 
Our study also showed that initiating treatment with a high baseline CD4 cell count 
was associated with development of discordant immunologic response. This finding 
is marred by conflicting findings in literature. In a study on the largest cohort of 
patients receiving HAART in resource poor settings (ART-LINC study) similar 
findings to our study were found (21). In addition another study from resource-rich 
setting, the UK-CHIC study also showed similar results to ours though discordant 
response was assessed at 8 months after initiating treatment (31). However most 
studies in resource-rich settings show contrary findings as low baseline CD4 cell 
count is associated with discordant immune response (2). The latter finding has 
gained biological plausibility as a low nadir pre-treatment CD4 cell count is 
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suggestive of more extensive depletion of CD4 cells in the gut-associated lymphoid 
tissue during acute HIV infection, which may be delayed or refractory to 
reconstitution with antiretroviral therapy (23). In addition genetic variability has also 
been investigated as a possible modulator of immunological recovery. However, the 
association between initiating treatment with a high baseline CD4 cell count and 
development of discordant immune response can be explained by the nonlinear 
nature of CD4 cell count increases after HAART initiation across the different 
baseline CD4 count strata (2). Another reason cited is that starting treatment at 
higher CD4 cell counts limits the scope for further rise (31).  
4.3.4 Baseline hemoglobin level as a risk factor for discordant immune response 
To our knowledge our study is the first to describe of an association between 
baseline hemoglobin level and discordant immune response. In our study moderate 
anemia classified as hemoglobin of between 8-9.4g/dl was associated with 1.6 
greater odds of developing a discordant immune response. The aetiology of anemia 
in HIV infection is multifactorial but is commonly due to underproduction of 
erythrocytes by the bone marrow stem cells (38). These stem cells are also 
responsible for production CD4 cells through the myeloid precursor cell (39). In 
addition erythrocytes of HIV infected individuals experience membrane changes 
which result in decreased fluidity of the cells leading to their premature destruction 
(40). This mechanism of membrane changes is similar to the one experienced by 
CD4 cells which also result in their destruction. These two mechanisms of poor 
production and membrane changes could explain the discordant immune response 
experienced by those with anemia when starting HAART. 
Anemia is common in HIV infection, mainly in advanced disease states (38). The fact 
that patients who were eligible for our analysis were of relatively advanced stage of 
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immunosuppression compared to those not analyzed (missing data at 6 months) 
could have biased our study to significance. In addition our analysis group had an 
older population compared to those with missing data at 6 months. 
However this finding should be viewed with caution as it failed to remain significant in 
the sensitivity analysis when definition of immune response was altered. 
4.4   Study limitations 
4.4.1 Technical limitations  
Our study in particular had limitations which are inherent to secondary data 
analysis. These include errors in the data entry which because of the nature 
of the study could not be rectified. These errors in data entry could have 
resulted in non-differential misclassification of patients as outcomes could be 
inaccurately measured. This could have bias the results towards the null. 
However such errors could have been evenly distributed among the groups 
and their influence on the results would have been minimal. 
 
Another problem plaguing secondary data analysis is that of missing data. 
However since this was at random, the influence on the results would have 
been minimal (see Table 4). 
 4.4.2   Epidemiological limitations 
 Selection bias could have influenced the findings in our study as only those 
presenting for follow up visits were available for analysis. There was also 
systematic difference between those eligible for analysis and those with 
missing data at 6 months as suggested by the greater proportion of those 
analyzed being of more advanced immune suppression than those with 
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missing data. This could have biased the results as those analyzed were 
more likely to develop the outcome of interest.  
 
The outcomes in this study were measured at between 3-6 months after 
initiation of treatment. It is possible that factors associated with discordant 
immune response at 3 months could be different to those at 6 months. It is 
unfortunate that due to the secondary nature of the data, we were unable to 
explore this possibility which could potentially influence our results. Similarly, 
we were unable to explore factors associated with discordant immune 
response at later times which also affects the generalizability of our findings.  
4.4.3 Statistical limitations 
We had a study sample of 810 participants. This small sample could have influenced 
our study findings. However we feel our sample was comparable to most studies 
done elsewhere. 
4.5 Generalizability 
The major limitations in interpreting and generalizing our study results are the 
following: 
4.5.1 Variation in the study designs 
 Study designs have been mainly secondary data analysis of prospectively 
collected data, prospective cohort studies and observational studies. All these 
studies are all plagued with their own flaws. 
4.5.2 Variations in study population  
Studies have also included treatment experienced (41), treatment naïve and 
at times mixed patients. In addition different studies have used patients who 
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have either used NRTI, NNRTI or have switched from a PI based regimen 
(42). 
4.5.3 Variation in the sample size 
Sample sizes have varied from as little as 162 by Piketty et al(43) to as much 
2 584 in the UK-CHIC study (31). 
4.5.4 Variation in the definition of outcomes 
The definition of good virologic response varied from 400- 1000copies/ml(41, 
42, 44) or 1 log10 copies/ml(41) decrease from baseline was used. The 
definition for CD4 count response also varied from 50-500cells/ul increase in 
CD4 cell count in some studies (11). 
4.5.5 Variation in the timing after HAART Initiation 
The timing after the initiation of HAART has ranged from 6 months – three 
year (45), hence the optimal time for assessing discordance is still unknown. 
4.6 Residual confounding.  
All factors of interest were initially examined in a univariate model to determine 
their association with development of discordant immune response. Significant 
factors at P≤0.2 were included in the multivariate logistic regression model 
where each factor of interest controlled for the confounding effect of the other. 
This method adjusted for confounding effect of several factors at the same time. 
Factors significant at the 5% level were then considered significant risk factors 
for development of discordant immune response. 
However, despite controlling for confounding, the residual confounding effect in 
the association between the risk factors identified and discordant immune 
response remains a possibility. This is because we did not examine or measure 
all factors associated with discordant immune response such as co-infection 
51 
 
with HTLV-1, GB virus C and genetic factors. This information was lacking in our 
database.  
4.7      Study strengths 
 Our sample size was large enough to have detected any significant findings. 
 Our study population was from two clinics from a densely populated area in 
the biggest district of Gauteng province making our study findings 
generalizable to many populations.  
 Our study used routine clinical data from Resource Limited Settings which 
make our findings applicable to adults receiving antiretroviral therapy at urban 
clinics in South Africa. 
4.8    Suggestion for further studies 
Our study showed a clinically significant association between baseline CD4 
cell count and discordant immune response. Moreover, it showed an 
association with baseline anemia which had not been described before to our 
knowledge. This finding will need further studies to confirm it as a risk factor 
which can be of use in resource-poor settings where it can be used for 
predicting patients who may develop the discordant immune response. 
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   Chapter five: Conclusion and Recommendations 
5.1 Conclusions 
In conclusion, our study showed that the prevalence of early discordant immune 
response was 24 % and that of concordant response to be 65%. Our study also 
showed that age, baseline CD4 count and baseline hemoglobin level were 
significantly associated with development of discordant immune response after 6 
months of initiating treatment. 
However no association was observed between gender, body mass index and 
HAART regimen which have been observed in other studies. 
5.2 Key points 
 Age is significant risk factor for developing discordant immune response after 
six months of HAART. 
 Baseline CD4 cell count is significant risk factor for developing discordant 
immune response after six months of HAART. 
 Initiating HAART with baseline moderate anemia is significantly associated 
with development of discordant immune response six months on. 
5.3 Summary   
Some studies have shown an association between discordant immune response and 
gender or body mass index. It should be noted that these studies had small sample 
sizes and did not measure other known confounders. Even though our study failed to 
demonstrate a significant association between HAART regimen and discordant 
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immune response in the multivariable model, its significance has been shown in 
several studies. This could be due few patients initiating treatment on Zidovudine 
based regimen. However Zidovudine based regimen was independently associated 
with discordant immune response. 
Regardless of the above, we feel our study findings outlined above are valid and 
unlikely to be due to chance, sampling bias or residual confounding. 
5.4 Recommendations 
5.4.1 Clinical management 
It is currently recommended that patients with discordant immune response on a new 
HAART regimen maintain their current regimens. Changing or intensifying the 
regimen has not been shown to have an effect on the CD4 cell count. Benefit has 
however been observed in changing those on leucopenic antiviral drugs like 
Zidovudine or Didanosine. Administration of human recombinant growth hormone 
has also been shown to be of benefit in chronically infected patients. In addition use 
of concomitant medications which are myelosuppressive such as Cotrimoxazole can 
be interrupted or substituted to confer some benefit to these patients. 
In view of the findings of our study we recommend that clinicians use hemoglobin 
which is available in resource-poor settings to predict patients who are likely to 
develop discordant immune response. These patients are at increased risk of 
developing an AIDS event compared to those with a concordant response hence 
require frequent clinical visits to detect opportunistic infections early. 
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Moreover we recommend for the development of a standardized definitions of 
discordant responses to permit for meaningful comparisons between studies to be 
made. 
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